Mylan's Antitrust Claims Nixed In Prilosec IP Suit

Law360, New York (May 21, 2010, 5:16 PM EDT) -- A federal judge has tossed Mylan Laboratories Inc.'s antitrust counterclaims and denied its bid for attorneys' fees in long-running multidistrict litigation brought by AstraZeneca AB accusing the generic-drug maker of infringing patents for gastric-acid inhibitor Prilosec.

Judge Barbara S. Jones of the U.S. District Court for the Southern District of New York on Wednesday granted AstraZeneca's December 2008 motion to dismiss with prejudice Mylan's accusations that AstraZeneca unlawfully perpetuated its monopoly power and forced generic manufacturers out of the omeprazole products market by launching sham patent...
To view the full article, register now.